Safety of coronavirus disease 2019 vaccines in 213 adult patients with sickle cell disease

Archive ouverte

Joseph, Laure | Corbasson, Anne | Manceau, Sandra | Khimoud, Djamal | Meunier, Benoit | Cheminet, Geoffrey | Lefrere, François | Jannot, Anne‐sophie | Lu, Estelle | Arlet, Jean‐Benoît

Edité par CCSD ; Wiley -

International audience. Given the lack of information about safety of the COVID-19 vaccines for sickle cell disease (SCD) patients, we sought to determine whether COVID-19 vaccine was associated with subsequent hospital admission for vaso-occlusive events (VOEs). We included 402 patients with SCD, including 88 regularly transfused. As of July 31, 2021, 213 (53.0%) of them had received a least one dose of COVID vaccine (Pfizer 93.0%). We showed similar risk of hospital admission for a VOE among vaccinated patients (whether transfused or not) and among a control group of non-vaccinated patients matched for age, sex and genotype.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion